CRISPR Therapeutics AG

NASDAQ: CRSP
$65.35
+$0.86 (+1.3%)
Closing price September 30, 2022
Barclays recently issued a few calls across multiple industries picking a couple winners and a couple losers.
Tuesday's additional top analyst upgrades and downgrades were on Bed Bath & Beyond, Clorox, CRISPR Therapeutics, LivePerson, Nike, Palantir Technologies, Tyson Foods and more.
One big Wall Street name thinks it has found a big winner in this gene-editing company, and the stock could benefit greatly going forward.
Thursday's additional top analyst upgrades and downgrades included American Tower, Coinbase, Snowflake, Southwest and more.
Wednesday's top analyst upgrades and downgrades included Albemarle, Camping World, eBay, EOG Resources, Etsy, Global Payments, IMAX, JPMorgan Chase, MetLife, Otis Worldwide, Salesforce, Wayfair and...
Thursday's top analyst upgrades and downgrades included Alcon, Array Technologies, AZEK, Boeing, Capital One Financial, Coinbase Global, Corning, Electronic Arts, Harley-Davidson, ON Semiconductor,...
Thursday's top analyst upgrades and downgrades included Airbnb, Alcoa, Beyond Meat, Fidelity National Information Services, Marriott International, Monster Beverage, Paramount Global, Shopify, Spirit...
Biotechnology was a huge laggard last year, but Truist Securities is out with its five top picks for 2022 that could see some sensational performance this year. Portfolio managers favor these...
A couple of Cathie Wood's ARK Invest exchange-traded funds bought nearly 60,000 shares of CRISPR Therapeutics on December 29 for $4.6 million.
Tuesday afternoon's top analyst upgrades and downgrades included Alibaba, Apple, AstraZeneca, Canopy Growth, CNX Resources, Murphy Oil, Ross Stores and Tesla.
Tuesday afternoon's analyst upgrades and downgrades included CRISPR, Editas, Esperion Therapeutics, Marriott Penn National Gaming and more.
A couple of Cathie Wood's ARK Invest exchange-traded funds bought over 675,000 shares of CRISPR Therapeutics on October 14.
A couple of Cathie Wood's ARK Invest exchange-traded funds bought over 400,000 shares of CRISPR Therapeutics on October 10.
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
The WallStreetBets community has been a resounding force in the market since January causing many investors to reevaluate their positions. Here's a look going into this trading session.